



Biosergen publishes interim report for fourth quarter 2023

Thursday, February 29, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the fourth quarter 2023. The interim report is available as an attached document and on the company website (www.biosergen.net)

Summary of the Interim Report for Q4 2023

TSEK	2023 Oct-Dec	2022 Oct-Dec	2023 Jan-Dec	2022 Jan-Dec
Other income	1.315	1.964	9.378	5.183
Profit/loss before depreciation (EBITDA)	-6.662	-12.491	-27.266	-39.987
Operating profit/loss before net financials	-6.662	-12.491	-27.037	-39.987
Net financials	193	87	229	109
Netprofit/loss for the period	-6.469	-12.432	-27.037	-39.906
Earnings per share (SEK)	-0,13	-0,40	-0,53	-1,28

Highlights during Q4 2023

- December 12, Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy

Highlights after the period

- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor

The Financial report can be found on our website: <http://biosergen.net/investors/filings>

For further information about Biosergen, please contact:

Tine Kold Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net

The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

ABOUT BIOSERGEN

Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen's mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year